Online citations, reference lists, and bibliographies.

Radiological Changes Following Second-line Zoledronic Acid Treatment In Breast Cancer Patients With Bone Metastases

Eitan Amir, Cari Whyne, Orit C Freedman, Michael Fralick, Ranjan Satish Kumar, Michael Hardisty, Mark Clemons
Published 2009 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
Initiation of bisphosphonate therapy in bisphosphonate-naïve patients is known to be associated with radiological changes such as increased bone density in both osteolytic and osteoblastic metastases. It is not known, however, whether switching from a second-generation bisphosphonate to a more potent agent is associated with similar changes. This study aimed to prospectively explore radiological changes, as assessed by thoracolumbar CT scanning, in patients switching from an early generation bisphosphonate (i.e., oral clodronate or intravenous pamidronate) to intravenous zoledronic acid. Patients with progressive bone metastases despite use of an earlier generation bisphosphonate were switched to zoledronic acid as part of a study to evaluate the palliative benefit of this intervention. Quantitative computed tomography (QCT) scanning of the thoracolumbar spine was carried out at baseline, and repeated 4 months after commencing zoledronic acid. The effect of this change of therapy was explored in terms of bone density, as well as volume of osteolytic and osteoblastic disease. Fifteen patients were assessed. Switching of bisphosphonate therapy was associated with a significant increase in bone density, and an increase in osteoblastic volume. There was an insignificant trend towards reduced osteolytic volume. In conclusion, switching from early generation bisphosphonates to a more potent agent is associated with radiological changes similar to those seen when commencing a bisphosphonate in treatment-naïve patients. This is consistent with the observed palliative benefit. The use of QCT may be of benefit in the monitoring of bone metastases.
This paper references
Osteoporosis as a late complication of allogeneic bone marrow transplantation
AE Hunter (1993)
10.1016/S1470-2045(04)01596-7
Assessment of therapeutic response in patients with metastatic bone disease.
Andrew R. Clamp (2004)
10.1200/JCO.1998.16.6.2038
Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.
Gabriel N. Hortobagyi (1998)
10.1016/j.jbiomech.2003.08.010
Mechanical properties, density and quantitative CT scan data of trabecular bone with and without metastases.
Tadashi S. Kaneko (2004)
10.1002/1097-0142(19900101)65:1<98::AID-CNCR2820650121>3.0.CO;2-K
Pathogenesis of vertebral metastasis and epidural spinal cord compression.
F Arguello (1990)
Zoledronic acid significantly reduces skeletal complications Clin Exp Metastasis
N Kohno (2005)
10.1056/NEJM199612123352401
Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.
Gabriel N. Hortobagyi (1996)
10.1118/1.2756939
Quantitative characterization of metastatic disease in the spine. Part II. Histogram-based analyses.
C. Whyne (2007)
10.1002/jbm.820281111
Correlations between orthogonal mechanical properties and density of trabecular bone: use of different densitometric measures.
Joyce H. Keyak (1994)
10.1016/j.radonc.2004.01.009
Computed tomography (CT) evaluation of breast cancer patients with osteolytic bone metastases undergoing palliative radiotherapy--a feasibility study.
Edward Chow (2004)
Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study.
Ragnar Hultborn (1999)
10.1016/S0936-6555(98)80113-1
Bone density: is it affected by orchidectomy and radiotherapy given for stage I seminoma of the testis?
J A Stutz (1998)
10.1200/JCO.2006.05.9212
Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
Mark Clemons (2006)
Skeletal changes during prolonged external irradiation: alterations in marrow, growth plate and osteoclast populations.
Anderson Nd (1979)
10.1002/jor.1100090507
Evaluation of orthogonal mechanical properties and density of human trabecular bone from the major metaphyseal regions with materials testing and computed tomography.
M J Ciarelli (1991)
10.1038/bjc.1997.488
Concomitant i.v. and oral clodronate in the relief of bone pain--a double-blind placebo-controlled study in patients with prostate cancer.
T. Kylmälä (1997)
10.1016/S0959-8049(97)10155-1
A randomised phase II study of oral pamidronate for the treatment of bone metastases from breast cancer.
Robert Coleman (1998)
10.1200/jco.1996.14.9.2552
Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.
Pier Franco Conte (1996)
10.1097/00007632-199001000-00001
Spinal Metastases: The Obvious, the Occult, and the Impostors
David Alan Wong (1990)
10.1200/JCO.1999.17.3.846
Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group.
Rachel Leigh Theriault (1999)
10.1038/bjc.1987.13
The clinical course of bone metastases from breast cancer.
Robert Coleman (1987)
10.1007/BF00351751
Osteodensitometry of vertebral metastases after radiotherapy using quantitative computed tomography
W Reinbold (1989)
10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G
Skeletal complications of malignancy.
Robert Coleman (1997)
10.1118/1.2746498
Quantitative characterization of metastatic disease in the spine. Part I. Semiautomated segmentation using atlas-based deformable registration and the level set method.
Michael Hardisty (2007)
10.1007/s00256-007-0388-1
A prospective analysis of CT density measurements of bone metastases after treatment with zoledronic acid
Carlo Cosimo Quattrocchi (2007)
10.1002/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z
Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials.
Allan Lipton (2000)
Development of Guidelines for the Prophylactic Treatment of Metastatically Involved Vertebral Bodies.
Cari M. Whyne (1998)
10.1056/NEJM199602223340802
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.
James R. Berenson (1996)
10.1002/1097-0142(19941201)74:11<2949::AID-CNCR2820741110>3.0.CO;2-Q
Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study.
Donna Glover (1994)
10.1007/s11547-007-0205-x
Bone metastases in breast cancer: higher prevalence of osteosclerotic lesions
Carlo Cosimo Quattrocchi (2007)



This paper is referenced by
10.1007/s10585-020-10049-9
CT based quantitative measures of the stability of fractured metastatically involved vertebrae treated with spine stereotactic body radiotherapy
Michael Hardisty (2020)
10.1016/j.jbo.2017.11.001
Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer
J Hilton (2018)
10.1007/s00330-017-5253-6
Early osteosclerotic changes predict chemotherapy response in non-small-cell lung cancer patients with bone metastases
Dailin Rong (2017)
10.1016/j.jbo.2012.02.001
Differential effect of zoledronic acid on normal trabecular and cortical bone density in oncologic patients with bone metastases
Carlo Cosimo Quattrocchi (2012)
10.1002/9781444345100.CH85
Metastatic/Myeloma Disease—Nonoperative Management
Harsha Malempati (2011)
10.1016/j.breast.2014.05.023
Bone health in breast cancer patients: a comprehensive statement by CECOG/SAKK Intergroup.
Tamara Rordorf (2014)
10.1097/MJT.0b013e3182456dff
Painful Boney Metastases
Howard S. Smith (2014)
Painful osseous metastases.
Howard S. Smith (2011)
10.1007/s00520-011-1230-9
Optimising the use of bone-targeted agents in patients with metastatic cancers: a practical guide for medical oncologists
Nathaniel Bouganim (2011)
10.3344/kjp.2013.26.3.223
Painful Boney Metastases
Howard S. Smith (2013)
10.2217/fon.09.138
Emerging therapeutic targets in breast cancer bone metastasis.
April A N Rose (2010)
10.1007/s10549-015-3646-2
A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer
Cindy Jacobs (2015)
10.1016/j.ijrobp.2016.09.029
Volume of Lytic Vertebral Body Metastatic Disease Quantified Using Computed Tomography-Based Image Segmentation Predicts Fracture Risk After Spine Stereotactic Body Radiation Therapy.
Isabelle Thibault (2017)
10.1007/s12149-012-0595-2
Evaluation of sequential FDG-PET/CT for monitoring bone metastasis of breast cancer during therapy: correlation between morphological and metabolic changes with tumor markers
Takashi Katayama (2012)
Semantic Scholar Logo Some data provided by SemanticScholar